Oriented implants containing poly(butylene succinate) and copolymer, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11878087-B2
Application number	US-201916290727-A
Country	US
Kind code	B2
Filing date	Mar 1, 2019
Priority date	Mar 1, 2018
Publication date	Jan 23, 2024
Grant date	Jan 23, 2024

Abstract

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

First claim

We claim:

1. An implant comprising fibers of a polymeric composition, wherein the polymeric composition comprises one or more 1,4-butanediol units and one or more succinic acid units, wherein the fibers comprise a monofilament fiber, a multifilament fiber, or a combination thereof, wherein the monofilament fiber has a tensile strength of 400 to 2,000 MPa and the multifilament fiber has a tenacity of greater than 4 grams/denier and less than 14 grams/denier, and
wherein the implant comprises a mesh, a film, a non-woven construct, a molded object, a patch, a tube, a laminate, or a pultruded profile.

2. The implant of claim 1 , wherein the fibers are braided or barbed.

3. The implant of claim 1 , wherein the implant comprises the mesh, and wherein the mesh is knitted or woven from the monofilament fibers and/or the multifilament fibers.

4. The implant of claim 1 , wherein the fibers are monoaxially or biaxially oriented.

5. The implant of claim 1 , wherein the implant is porous.

6. The implant of claim 2 , wherein a tensile strength of the fibers is between 500 MPa and 1,200 MPa.

7. The implant of claim 1 , wherein the fibers have a Young's Modulus of at least 600 MPa, but less than 3 GPa.

8. The implant of claim 1 , wherein the mesh has a burst strength between 1 kgf or a Taber stiffness between 0.01 and 10 Taber stiffness units.

9. The implant of claim 1 wherein: (a) there is no pitting of a surface of the implant during degradation in vivo, under physiological conditions, for a period of 4 weeks or (b) when implanted under physiological conditions, in vivo for a period of 4 weeks, dimensions of the implant do not shrink more than 5% of their initial values.

10. The implant of claim 1 , wherein the polymeric composition further comprises (a) one or more of the following: a second diacid unit, a second diol unit, 1,3-propanediol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid, and oxalic acid; (b) one or more of the following: a branching agent, a cross-linking agent, a chain extender agent, and a reactive blending agent; or (c) a hydroxycarboxylic acid unit.

11. The implant of claim 10 , wherein the branching agent, cross-linking agent, or chain extender unit is selected from one or more of the following: malic acid, maleic acid, fumaric acid, trimethylol propane, trimesic acid, citric acid, glycerol propoxylate, and tartaric acid.

12. The implant of claim 1 , wherein the polymeric composition comprises succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-citric acid copolyester, succinic acid-1,4-butanediol-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid copolyester further comprising citric acid, tartaric acid, or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-citric acid copolyester, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyester, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyester further comprising citric acid, tartaric acid, or combinations thereof.

13. The implant of claim 1 , wherein the implant further comprises a plasticizer, nucleant, coating, dye, medical marker, bioactive agent, therapeutic agent, diagnostic agent, prophylactic agent, contrast agent, radiopaque marker, radioactive substance, anti-adhesion agent, hyaluronic acid, antibiotic, rifampin, minocycline, collagen, hydroxyapatite, or an absorbable polymer comprising one or more of the following monomers: glycolic acid, lactic acid, trimethylene carbonate, p-dioxanone, ε-caprolactone, 4-hydroxybutyric acid, and 3-hydroxybutyric acid.

14. The implant of claim 1 , wherein the polymeric composition: (i) excludes urethane bonds, (ii) is not prepared with a diisocyanate, (iii) comprises 1-500 ppm of one or more, or all, of the following: silicon, titanium, and zinc, (iv) excludes tin or (v) is not a blend of two or more polymers.

15. The implant of claim 1 , wherein the polymeric composition has a melt temperature between 100° C. and 150° C.

16. The implant of claim 1 , wherein the implant is selected from the group consisting of: a suture, a barbed monofilament suture, a braided suture, a mesh suture, a wound closure device, a patch, a wound healing device, a wound dressing, a burn dressing, an ulcer dressing, a skin substitute, a hemostat, a tracheal reconstruction device, an organ salvage device, a dural patch or substitute, a nerve regeneration or repair device, a hernia repair device, a hernia mesh, a hernia plug, an inguinal hernia plug, a device for temporary wound or tissue support, a tissue engineering scaffold, a guided tissue repair/regeneration device, an anti-adhesion membrane or barrier, a tissue separation membrane, a retention membrane, a sling, a device for pelvic floor reconstruction, a device for treatment of pelvic organ prolapse, an urethral suspension device, a device for treatment of urinary incontinence, a device for treatment of stress urinary incontinence, a bladder repair device, a bulking or filling device, a bone marrow scaffold, a bone plate, a fixation device for an implant, a ligament repair device or augmentation device, an anterior cruciate ligament repair device, a tendon repair device or augmentation device, a rotator cuff repair device, a meniscus repair or regeneration device, an articular cartilage repair device, an osteochondral repair device, a spinal fusion device, a cardiovascular patch, a catheter balloon, a vascular closure device, an intracardiac septal defect repair device, an atrial septal defect repair device a patent foramen ovale closure device, a left atrial appendage closure device, a pericardial patch, a vein valve, a heart valve, a vascular graft, a myocardial regeneration device, a periodontal mesh, a guided tissue regeneration membrane for periodontal tissue, an ocular cell implant, an imaging device, a cochlear implant, an anastomosis device, a cell seeded device, a cell encapsulation device, a controlled release device, a drug delivery device, a plastic surgery device, a mastopexy device, a breast reconstruction device, a breast augmentation device, a breast reduction device, a breast implant, a device for removing, reshaping and reorienting breast tissue, a device for breast reconstruction following mastectomy with or without breast implants, a facial reconstructive device, a forehead lift device, a brow lift device, an eyelid lift device, a rhytidectomy device, a thread lift device, a device to lift and support sagging areas of the face and brow, a rhinoplasty device, a device for malar augmentation, an otoplasty device, a neck lift device, a mentoplasty device, a buttock lift device, a cosmetic repair device, and a device for facial scar revision.

17. The implant of claim 16 , wherein the implant is a braided suture comprising a multifilament fiber, wherein the breaking strength of the braided suture is from 40_N to 270_N.

18. The implant of claim 1 , wherein the implant contains less than 20 endotoxin units as determined by the limulus amebocyte lysate (LAL) assay.

19. The implant of claim 1 wherein the fibers are multifilament fibers.

20. The implant of claim 10 , wherein the polymeric composition comprises the hydroxycarboxylic acid unit, and wherein the hydroxycarboxylic acid unit has two carboxyl groups and one hydroxyl group, two hydroxyl groups and one carboxyl group, three carboxyl groups and one hydroxyl group, or two hydroxyl groups and two carboxyl groups.

21. The implant of

Assignees

• Tepha Inc

Inventors

• Williams Simon F
• Rizk Said
• Martin David P

Classifications

• A61L27/18 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

• A61F2/0045

  Support slings · CPC title

• A61F2/0063

  Implantable repair or support meshes, e.g. hernia meshes · CPC title

• A61F2/12

  Mammary prostheses · CPC title

• A61L17/06

  At least partially resorbable materials · CPC title